Antibacterial and antiyeast compounds from marine-derived bacteria

Marine Drugs

Volumn 12, Issue 5, 2014, Pages 2913-2921

  Mondol, Muhammad Abdul Mojid ^a   Shin, Hee Jae ^b,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Korea Research Institute of Ships and Ocean Engineering   (South Korea)

^c University of Science and Technology (UST)   (South Korea)

Author keywords

Antibiotics; Antimicrobial activity; Marine microorganisms; NMR data

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; LAURAMIDE DIETHANOLAMINE; MACROLACTIN A1; MACROLACTIN B1; UNCLASSIFIED DRUG; SEA WATER;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CARBON NUCLEAR MAGNETIC RESONANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG STRUCTURE; IN VITRO STUDY; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTON NUCLEAR MAGNETIC RESONANCE; BACILLUS; BACTERIA; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SACCHAROMYCES CEREVISIAE; STREPTOMYCES; YEAST;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACILLUS; BACTERIA; MICROBIAL SENSITIVITY TESTS; SACCHAROMYCES CEREVISIAE; SEAWATER; STREPTOMYCES; WATER MICROBIOLOGY; YEASTS;

EID: 84901472614     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12052913     Document Type: Article

References (22)

1. Edmond, M.B.; Ober, J.F.; Weinbaum, D.L.; Pfaller, M.A.; Hwang, T.; Sanford, M.D.; Wenzel, R.P. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection. Clin. Infect. Dis. 1995, 20, 1126-1133.
2. Leclercq, R. Epidemiological and resistance issues in multidrug-resistant Staphylococci and Enterococci. Clin. Microbiol. Infect. 2009, 15, 224-231.
3. Demain, A.L.; Sanchez, S. Microbial drug discovery: 80 Years of progress. J. Antibiot. 2009, 62, 5-6.
4. Katz, M.L.; Mueller, L.V.; Polyakov, M.; Weinstock, S.F. Where have all the antibiotic patents gone. Nat. Biotechnol. 2006, 24, 1529-1531. (Pubitemid 44967476)
5. Kong, D.X.; Jiang, Y.Y.; Zhang, H.Y. Marine natural products as sources of novel scaffolds: Achievement and concern. Drug Discov. Today 2010, 15, 884-886.
6. Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural products. Nat. Rev. Drug Discov. 2009, 8, 69-85.
7. Bhatnagar, I.; Kim, S.K. Immense essence of excellence: Marine microbial bioactive compounds. Mar. Drugs 2010, 8, 2673-2701.
8. Liu, Y. Renaissance of marine natural product drug discovery and development. J. Mari. Sci. Res. Dev. 2012, doi:10.4172/2155-9910.1000e106.
9. Trowbridge, J.R.; Falk, R.A.; Krems, I.J. Fatty acid derivatives of diethanolamine. J. Org. Chem. 1955, 20, 990-995.
10. Mondol, M.A.M.; Tareq, F.S.; Kim, J.-H.; Lee, M.A.; Lee, H.-S.; Lee, Y.-J.; Lee, J.-S.; Shin, H.J. Cyclic ether-containing macrolactins, antimicrobial 24-membered isomeric macrolactones from a marine Bacillus sp. J. Nat. Prod. 2011, 74, 2582-2587.
11. Schneider, K.; Chen, X.-H.; Vater, J.; Franke, P.; Nicholson, G.; Borriss, R.; Süssmuth, R.D. Macrolactin is the polyketide biosynthesis product of the pks2 cluster of Bacillus amyloliquefaciens FZB42. J. Nat. Prod. 2007, 70, 1417-1423. (Pubitemid 47584580)
12. α- caproyl-L-arginine)-1,3-propanediamine dihydrochloride and chlorhexidine dihydrochloride against Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. 2006, 57, 691-698.
13. Zheng, C.-J.; Lee, S.; Lee, C.-H.; Kim, W.-G. Macrolactins O-R, glycosylated 24-membered lactones from Bacillus sp. AH159-1. J. Nat. Prod. 2007, 70, 1632-1635. (Pubitemid 350155417)
14. Kabara, J.J. Structure-function relationships of surfactants as antimicrobial. J. Soc. Cosmet. Chem. 1978, 29, 733-741.
15. Mondol, M.A.M.; Shin, H.J.; Islam, M.T. Diversity of secondary metabolites from marine Bacillus species: Chemistry and biological activity. Mar. Drugs 2013, 11, 2846-2872.
16. Nagao, T.; Adachi, K.; Sakai, M.; Nishijima, M.; Sano, H. Novel macrolactins as antibiotic lactones from a marine bacterium. J. Antibiot. 2001, 54, 333-339. (Pubitemid 32427931)
17. Romero-Tabarez, M.; Jansen, R.; Sylla, M.; Lunsdorf, H.; Haubler, S.; Santosa, D.A.; Timmis, K.N.; Molinari, G. 7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia. Antimicrob. Agents Chemother. 2006, 50, 1701-1709.
18. Jaruchoktaweechai, C.; Suwanborirux, K.; Tanasupawatt, S.; Kittakoop, P.; Menasveta, P. New macrolactins from a marine Bacillus sp. Sc026. J. Nat. Prod. 2000, 63, 984-986.
19. Mondol, M.A.M.; Kim, J.-H.; Lee, M.A.; Lee, H.-S.; Lee, Y.-J.; Shin, H.J. Macrolactin W, a new antibacterial macrolide from a marine Bacillus sp. Bioorg. Med. Chem. Lett. 2011, 21, 3832-3835.
20. Lee, Y.B.; Park, H.J.; Kwon, M.J.; Jeong, S.K.; Cho, S.H. Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids. Eur. J. Dermatol. 2011, 21, 710-716.
21. Uchida, Y.; Holleran, W.M.; Elias, P.M. On the effects of topical synthetic pseudoceramides: comparison of possible keratinocyte toxicities provoked by the pseudoceramides, PC104 and BIO391, and natural ceramides. J. Dermatol. Sci. 2008, 51, 37-43.
22. Mizushima, H.; Fukasawa, J.-I.; Suzuki, T. Thermotropic behavior of stratum corneum lipids containing a pseudo-ceramide. Lipids 1995, 30, 327-332.